OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Partner with IP law firm MBHB and the co-chair of its biotechnology and pharmaceuticals practice group
Issue represents a potential threat in fighting future pandemics.
Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?